The user shared progress on hair regrowth using oral dutasteride, oral minoxidil, and verteporfin procedures. They reported some regrowth after 6-9 months of treatment.
The user is experiencing increased hair loss and was diagnosed with male pattern baldness. They are considering using oral or topical finasteride to manage the condition and are contemplating cutting their hair short.
The user experienced significant hair regrowth after 7 months using oral finasteride, minoxidil, and microneedling. They are considering dutasteride but plan to continue with finasteride for a year before making changes.
The conversation is about a user's progress with hair regrowth using oral minoxidil and finasteride over two years. The user experienced significant improvement without side effects, except for increased libido, and plans to continue treatment.
Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.
User is 1.5 months into using oral minoxidil and finasteride for hair regrowth, along with dermarolling. They report good progress and seek advice on whether new hairs will thicken.
User starts Nuclear Stack treatment for hair loss, including Dutasteride, Minoxidil, RU58841, Derminator 2, and supplements. Seeks advice on storing and dosing RU58841.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
The user experienced significant hair regrowth over four months using oral finasteride, oral minoxidil, micro-needling, and rosemary oil. They reported no side effects and emphasized the importance of continuing the treatment to maintain results.
The user observed some regrowth and longer baby hairs after one month of using finasteride, despite experiencing increased shedding. They noted no side effects except for clear semen.
After nearly four months on finasteride, a user noticed improved hair quality but developed nipple puffiness, suggesting early signs of gynecomastia. They considered switching to other treatments like CB-03-01 or RU58841 and contemplated consulting an endocrinologist about aromatase inhibitors.
Minoxidil, finasteride, dutasteride, and microneedling are commonly used for temple regrowth, with varying results and timelines. Consistency and patience are emphasized, with some users seeing progress after several years.
The user is considering switching from topical finasteride to oral finasteride and is seeking advice on whether to transition directly or use both forms temporarily. They express concern about potential side effects.
A 20-year-old male experienced early hair thinning due to male pattern baldness and successfully thickened his hair using oral finasteride and topical minoxidil. The conversation highlights the importance of early action and overcoming fear of medication side effects.
PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.
A 21-year-old male with a thyroid condition noticed his hair thinning uniformly without a receding hairline. He is considering using a 5ARI to prevent further baldness if he starts TRT.
PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
The conversation is about the claim that oral minoxidil can make hair grow on bones. The conclusion is that this claim is not true, as evidenced by the user's head being bald while the body is furry.
A user shared their 5-month hair loss treatment progress using oral finasteride, Regaine foam, 2DDR serum, and microneedling, noting improvements in hair growth at the crown and front. They are considering increasing microneedling frequency or adding a shampoo to their routine.
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.
The conversation discusses using a violet ray device for hair regrowth, citing a case where zinc ion treatments showed promising results. It also mentions similar devices like the Growcombr and niostem helmet.
The user experienced severe hair shedding despite using oral finasteride, minoxidil, dutasteride, and RU58841, and was diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD). They are considering switching to topical treatments due to the ineffectiveness of their current regimen.
PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.
Temporal peaks are crucial for a natural-looking hair transplant, but they are challenging to achieve due to the need for precise angles and appropriate hair thickness. Many users emphasize the importance of finding a skilled surgeon and using finasteride to maintain hairline stability.
A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.
Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.
A 28-year-old male with a family history of baldness is deciding whether to start finasteride now or wait for visible hair changes. He is considering starting finasteride immediately to proactively address potential hair loss.